Medtronic is proudly touting FDA approval of its MiniMed 670G system, the world’s first “Hybrid Closed Loop insulin delivery system” to be made available anywhere. The system runs Medtronic’s SmartGuard HCL algorithm that calculates insulin delivery times and dosage amounts while letting patients take as much control over the pump as required. In the most automated mode the patient has to input carbohydrate counts following every meal, confirm recommended bolus changes, and once in a while calibrate the sensor.
The sensor used is Medtronic’s Guardian Sensor that works for an entire week without having to be switched, and that features self-checking functions to make sure it stays accurate while in use.
From Medtronic’s announcement:
The system is approved for the treatment of people with type 1 diabetes fourteen years of age and older with ongoing studies to expand the indication to additional patient populations. Medtronic will begin commercial release of the MiniMed 670G system in the spring of 2017 with system availability increasing over time. This timeline ensures payer coverage, market and manufacturing readiness, as well as appropriate training of employees, clinicians, educators and patients on the new system. As the company moves toward initial commercial release and subsequently to full production, users of the MiniMed 630G system will be eligible for a Priority Access Program to the MiniMed 670G system as their experience with our newest hardware platform will facilitate an optimal transition. Regulatory approval of the MiniMed 670G is expected outside of the U.S. in the summer of 2017.